← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.13T	3,571	+104	+3%	$707B
2	2 Pfizer PFE $169B	2,881	-2	-0.1%	$105B
3	3 Amgen AMGN $238B	2,791	+69	+3%	$129B
4	4 Novo Nordisk NVO $174B	1,865	+118	+7%	$47.9B
5	5 McKesson MCK $116B	1,635	+67	+4%	$65.2B
6	6 Becton Dickinson BDX $52.5B	1,588	-17	-1%	$59.2B
7	7 Regeneron Pharmaceuticals REGN $82.4B	1,335	+23	+2%	$98.9B
8	8 AstraZeneca AZN $260B	1,213	+70	+6%	$39B
9	9 Conagra Brands CAG $6.82B	872	+24	+3%	$11.7B
10	10 West Pharmaceutical WST $26.9B	777	-1	-0.1%	$22.4B
11	11 ResMed RMD $33.9B	773	+55	+8%	$16.4B
12	12 Lamb Weston LW $7.47B	755	-35	-4%	$11.7B
13	13 DaVita DVA $11.9B	561	+16	+3%	$10.6B
14	14 Teva Pharmaceutical Industries Limited TEVA $48.2B	534	+53	+11%	$9.88B
15	15 DELISTED CATALENT, INC. CTLT	448	+6	+1%	$10.3B
16	16 BellRing Brands BRBR $1.04B	447	+25	+6%	$7.06B
17	17 DELISTED WK Kellogg Co KLG	390	-14	-3%	$1.19B
18	18 Viking Therapeutics VKTX $3.44B	387	+12	+3%	$4.26B
19	19 Embecta EMBC $369M	362	-10	-3%	$697M
20	20 Inspire Medical Systems INSP $2B	325	-3	-0.9%	$4.23B
21	21 Hims & Hers Health HIMS $6.61B	298	+53	+22%	$2.75B
22	22 Amphastar Pharmaceuticals AMPH $1.13B	269	-1	-0.4%	$1.37B
23	23 Madrigal Pharmaceuticals MDGL $10.7B	257	-11	-4%	$6.41B
24	24 Opko Health OPK $1.16B	232	+6	+3%	$228M
25	25 Biohaven BHVN $1.72B	225	-17	-7%	$2.88B